
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc is positioned for strong future revenue growth, with projections estimating total revenue of $23 million for 2025, driven by increasing placements of EksoNR devices and the successful navigation of CMS claims for Indego Personal. The company witnessed a promising 21%-24% quarter-over-quarter revenue growth, reaching $4.1 million in Q3 2024, signaling a recovery from previous delays in capital purchases. Additionally, the strategic partnership aimed at expanding the market for Indego and anticipated increased demand for EksoNR in Europe further reinforces the optimistic outlook for long-term value creation.
Bears say
Ekso Bionics Holdings Inc experienced a 2% year-over-year decline in total revenue, falling to $17.9 million in 2024 from a record $18.3 million in 2023, primarily due to reduced enterprise sales influenced by erratic procurement cycles. Although the company saw notable revenue growth in Europe, especially in France, this was insufficient to counterbalance the overall decline in revenue. Additionally, the reported loss on the revaluation of warrant liabilities further underscores the company's financial challenges and contributes to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares